On the basis of our recent study 33, we categorized PCa patients into three immune subtypes and observed an obvious prevalence of TP53 mutations, particularly the p.R248Q variant, within the immunosuppressed and nonimmune/immuneless subgroups. Here, TP53 is linked to posterior cortical atrophy.